Why Abbott Is Poised to Outperform

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$52.6 billion

Industry

Health care equipment

Trailing-12-Month Revenue

$39.4 billion

Management

Chairman/CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (average, past 3 years)

22.3%

Cash/Debt

$11.5 billion / $16.3 billion

Dividend Yield

0.9%

Competitors

Johnson & Johnson
Merck
Sanofi


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97%of the 2,658 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.

A couple of months ago, one of those Fools, BuilderJS, succinctly summed up the Costco bull case for our community:

Compelling business model -- limited selection focused on value to the customer. Outstanding leadership and corporate culture that promotes business continuity. Excellent execution -- from the top notch merchandising, to the ability to negotiate with suppliers to the responsible growth plans.

Of course, this short pitch doesn't even come close to telling the entire story for Abbott. You're in luck, though. The Fool's brand new premium report on Abbott tells all sides of the story for one of the most powerful health care companies in the world. You can grab your copy now, which comes with free updates for 12 months, by just clicking here.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Abbott Is Poised to Outperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners